People with advanced or recurrent endometrial cancer (also known as womb or uterine cancer) will now have access to dostarlimab as a second-line treatment through the NHS following a new recommendation from the National Institute for Health and Care Excellence (NICE).
This is welcome news about an additional treatment option that can help people with advanced cancer, or whose cancer has come back, live well for longer.
What is Dostarlimab?
Dostarlimab is an immunotherapy drug that helps the immune system recognise and attack cancer cells.
What does this mean?
Dostarlimab has now been recommended by the National Institute for Health and Care Excellence (NICE) for routine use on the NHS in England as a second-line treatment option. Previously, it was only available to some patients through the Cancer Drugs Fund for this purpose.
This recommendation will affect people with advanced or recurrent womb cancer that is called mismatch repair deficient (dMMR), who need further treatment after first-line treatment with chemotherapy.
What is the Cancer Drugs Fund?
The Cancer Drugs Fund gives people access to promising cancer treatments while further evidence is collected. Once enough evidence is available, NICE reviews the treatment again to decide whether it should become routinely available on the NHS.
Peaches Womb Cancer Trust follows developments in womb cancer treatment closely. We will continue working with researchers, clinicians and the wider womb cancer community to support progress in treatment and ensure the voices of people affected by womb cancer continue to shape research and decision-making.
